L19IL2
As of the edition of 20 October 2026, L19IL2 is a drug: in active development; acts on FN1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Unknown
- Registered trials
- 13, 1 stopped early
- Disease areas
- Cancer; Skin and connective tissue; Digestive system; Infections; Pregnancy and women's health; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| FN1 | Fibronectin | P02751 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 0 | 2 | 0 |
| Phase 2 | 10 | 2 | 4 | 1 |
| Phase 3 | 1 | 0 | 1 | 0 |
| All trials | 13 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Philogen | Lead sponsor of trials | 2005 to now |